A self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the Department of Pharmacy and Biotechnology of the Università di Bologna (UNIBO), the first Brazil-Bologna joint laboratory dedicated to the development of new drugs for the treatment of Alzheimer's disease.
São Paulo Research Foundation Oct 17 2024 A self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the Department of Pharmacy and Biotechnology of the Università di Bologna , the first Brazil-Bologna joint laboratory dedicated to the development of new drugs for the treatment of Alzheimer's disease.
"We need to integrate the concept of sustainability into the search for bioactive molecules. This must be the keyword," said Bolognesi in her presentation. "If we adopt waste as a raw material for drug development, the products resulting from the research will be inherently sustainable." Neglected diseases Luiz Carlos Dias, a professor at the State University of Campinas , was another member of the panel. He presented the work of an international consortium created to support the search for new drugs against Chagas disease and malaria. The initiative brings together UNICAMP, USP and two non-profit organizations: the Drugs for Neglected Diseases Initiative and the Medicines for Malaria Venture .
Related StoriesDias reflects that the group's challenges are great and the goals are ambitious: to develop low-cost drugs that are safe enough to be used by children and pregnant women, who are among the main populations affected by these neglected diseases. She said that the pathogen spread throughout Italy during the COVID-19 pandemic, a phenomenon that was also observed in Brazil . "We're trying to implement a surveillance system to limit its spread," she said.
Write Comment
Alzheimer's Disease Antimicrobial Resistance Biotechnology